Effects of 1-Year Treatment with Cyclophosphamide on Outcomes at 2 Years in Scleroderma Lung Disease

Rationale: The Scleroderma Lung Study enrolled 158 patients with scleroderma-related interstitial lung disease in a placebo-controlled trial of oral cyclophosphamide (CYC). Although treatment-related benefits in pulmonary function, skin scores, and patient-centered outcomes were demonstrated after 1...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Päätekijät: Tashkin, Donald P., Elashoff, Robert, Clements, Philip J., Roth, Michael D., Furst, Daniel E., Silver, Richard M., Goldin, Jonathan, Arriola, Edgar, Strange, Charlie, Bolster, Marcy B., Seibold, James R., Riley, David J., Hsu, Vivien M., Varga, John, Schraufnagel, Dean, Theodore, Arthur, Simms, Robert, Wise, Robert, Wigley, Fred, White, Barbara, Steen, Virginia, Read, Charles, Mayes, Maureen, Parsley, Ed, Mubarak, Kamal, Connolly, M. Kari, Golden, Jeffrey, Olman, Mitchell, Fessler, Barri, Rothfield, Naomi, Metersky, Mark, Khanna, Dinesh, Li, Ning, Li, Gang
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: American Thoracic Society 2007
Aiheet:
E. Interstitial Lung Disease
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC2078679/
https://ncbi.nlm.nih.gov/pubmed/17717203
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1164/rccm.200702-326OC
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia